Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiang Guan

Showing results (171-180 of 181) with videos related to

Pageof 19
Sort By:
Chinese Medical Journal|July 26, 2021
Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trialYa-Jun Shu, Jian-Feng He, Rong-Juan Pei, et al.
Gut|May 20, 2015
A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradicationKai-feng Pan, Lian Zhang, Markus Gerhard, et al.
Emerging Microbes & Infections|June 10, 2022
Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trialXuan-Yi Wang, Syed Faisal Mahmood, Fang Jin, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|November 19, 2021
A method establishment and comparison of in vivo lung cancer model development platforms for evaluation of tumour metabolism and pharmaceutical efficacyTu-Liang Liang, Run-Ze Li, Chu-Tian Mai, et al.
Eclinicalmedicine|January 3, 2024
Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos)Yi Fang, Jing-Xin Li, Davone Duangdany, et al.
Gut|June 30, 2026
<i>Helicobacter pylori</i> infection, treatment and colorectal cancer risk by genetic predisposition: evidence from two randomised trialsXuan Han, Heng-Min Xu, Zong-Chao Liu, et al.
Signal Transduction and Targeted Therapy|February 5, 2025
Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trialRun-Cong Nie, Shu-Qiang Yuan, Ya Ding, et al.
Signal Transduction and Targeted Therapy|March 18, 2026
M6A-modified circArhgap26 attenuates cardiac ischemia‒reperfusion injury by suppressing plakophilin-1 palmitoylationMing-Yu Zhang, Dong-Ni Ji, Wen-Yi Qi, et al.
Nature Medicine|July 30, 2024
Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trialKai-Feng Pan, Wen-Qing Li, Lian Zhang, et al.
Nature Medicine|January 3, 2024
Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trialShu-Qiang Yuan, Run-Cong Nie, Ying Jin, et al.
Pageof 19

Showing results (171-180 of 181) with videos related to

Sort By:
Pageof 19
Chinese Medical Journal|July 26, 2021
Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trialYa-Jun Shu, Jian-Feng He, Rong-Juan Pei, et al.
Gut|May 20, 2015
A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradicationKai-feng Pan, Lian Zhang, Markus Gerhard, et al.
Emerging Microbes & Infections|June 10, 2022
Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trialXuan-Yi Wang, Syed Faisal Mahmood, Fang Jin, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|November 19, 2021
A method establishment and comparison of in vivo lung cancer model development platforms for evaluation of tumour metabolism and pharmaceutical efficacyTu-Liang Liang, Run-Ze Li, Chu-Tian Mai, et al.
Eclinicalmedicine|January 3, 2024
Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos)Yi Fang, Jing-Xin Li, Davone Duangdany, et al.
Gut|June 30, 2026
<i>Helicobacter pylori</i> infection, treatment and colorectal cancer risk by genetic predisposition: evidence from two randomised trialsXuan Han, Heng-Min Xu, Zong-Chao Liu, et al.
Signal Transduction and Targeted Therapy|February 5, 2025
Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trialRun-Cong Nie, Shu-Qiang Yuan, Ya Ding, et al.
Signal Transduction and Targeted Therapy|March 18, 2026
M6A-modified circArhgap26 attenuates cardiac ischemia‒reperfusion injury by suppressing plakophilin-1 palmitoylationMing-Yu Zhang, Dong-Ni Ji, Wen-Yi Qi, et al.
Nature Medicine|July 30, 2024
Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trialKai-Feng Pan, Wen-Qing Li, Lian Zhang, et al.
Nature Medicine|January 3, 2024
Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trialShu-Qiang Yuan, Run-Cong Nie, Ying Jin, et al.
Pageof 19